Seminars in Nuclear Medicine
Volume 39, Issue 6 , Pages 416-430 , November 2009

Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases

  • Sue Chua, MBBS, BSc, MRCPCH, FRCR

      Affiliations

    • Department of Nuclear Medicine and PET, The Royal Marsden Hospital NHS Foundation Trust, Surrey, United Kingdom
    • Corresponding Author InformationAddress reprint requests to Sue Chua, MBBS, BSc, MRCPCH, FRCR, Department of Nuclear Medicine, PET, and Radiology, The Royal Marsden NHS Foundation Trust, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    • ,
  • Gopinath Gnanasegaran, MD

      Affiliations

    • Department of Nuclear Medicine and PET, Guy's and St. Thomas Hospital NHS Foundation Trust, London, United Kingdom
    • ,
  • Gary J.R. Cook, MD, FRCR

      Affiliations

    • Department of Nuclear Medicine and PET, The Royal Marsden Hospital NHS Foundation Trust, Surrey, United Kingdom

References 

  1. Kosuda S, Kaji T, Yokoyama H, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI?. J Nucl Med. 1996;37:975–978
  2. Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37
  3. Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: Whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol. 2007;17:939–949
  4. Bybel B, Brunken RC, DiFilippo FP, et al. SPECT/CT imaging: Clinical utility of an emerging technology. Radiographics. 2008;28:1097–1113
  5. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135–142
  6. Pezeshk P, Sadow CA, Winalski CS, et al. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. Acad Radiol. 2006;13:1011–1015
  7. Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31–37
  8. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-fluoride: Applying new technology to an old tracer. J Nucl Med. 2008;49:68–78
  9. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–1804
  10. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36:73–92
  11. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–278
  12. Even-Sapir E, Mishani E, Flusser G, et al. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–469
  13. Schirrmeister H, Arslandemir C, Glatting G, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:964–968
  14. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–1629
  15. De Maeseneer M, Lenchik L, Everaert H, et al. Evaluation of lower back pain with bone scintigraphy and SPECT. Radiographics. 1999;19:901–912
  16. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: Lung cancer. Q J Nucl Med Mol Imaging. 2004;48:119–142
  17. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264–271
  18. Vinjamuri M, Craig M, Campbell-Fontaine A, et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer?. Clin Lung Cancer. 2008;9:30–34
  19. Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: Positron emission tomography. Clin Orthop Relat Res. 2003;415(suppl):S120–S128
  20. Cheran SK, Herndon JE, Patz EF. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004;44:317–325
  21. Algra PR, Heimans JJ, Valk J, et al. Do metastases in vertebrae begin in the body or the pedicles? (Imaging study in 45 patients). AJR Am J Roentgenol. 1992;158:1275–1279
  22. Bruzzi JF, Komaki R, Walsh GL, et al. Imaging of non-small cell lung cancer of the superior sulcus (Part 2: Initial staging and assessment of resectability and therapeutic response). Radiographics. 2008;28:561–572
  23. Zhu X-x, Chen Y-q, Chen L-h. [Value of integrated positron-emission tomography and computed tomography in gross tumor volume delineation for radiotherapy for bone metastasis]. Di Yi Jun Yi Xue Xue Bao. 2004;24:700–702
  24. Hetzel M, Arslandemir C, Konig H-H, et al. F-18 NaF PET for detection of bone metastases in lung cancer: Accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206–2214
  25. Muresan MM, Olivier P, Leclere J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer. 2008;15:37–49
  26. Tickoo SK, Pittas AG, Adler M, et al. Bone metastases from thyroid carcinoma: A histopathologic study with clinical correlates. Arch Pathol Lab Med. 2000;124:1440–1447
  27. Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroidology. 1999;9:1227–1235
  28. Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67:501–508
  29. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–967
  30. Ito S, Kato K, Ikeda M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889–895
  31. de Geus-Oei L-F, Oei H-Y, Hennemann G, et al. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2002;29:768–774
  32. Schirrmeister H, Buck A, Guhlmann A, et al. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroidology. 2001;11:677–683
  33. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115–132
  34. Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25:1177–1182
  35. Zanotti-Fregonara P, Rubello D, Hindie E. Bone metastases of differentiated thyroid cancer: The importance of early diagnosis and 131I therapy on prognosis. J Nucl Med. 2008;49:1902–1903
  36. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–1442
  37. Conti PS, Durski JM, Bacqai F, et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroidology. 1999;9:797–804
  38. Grunwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroidology. 1997;7:327–335
  39. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–76
  40. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study. Eur J Nucl Med. 1999;26:1547–1552
  41. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498–505
  42. Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 2002;9:913–921
  43. Freudenberg LS, Antoch G, Jentzen W, et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092–2098
  44. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol. 2000;164:1505–1508
  45. Zekri J, Ahmed N, Coleman RE, et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19:379–382
  46. Han K-R, Pantuck AJ, Bui MHT, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314–319
  47. Mitchell MS. Chemotherapy in combination with biomodulation: A 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol. 1992;19:80–87
  48. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for follow up after nephron sparing surgery for sporadic renal cell carcinoma. J Urol. 1997;157:2067–2070
  49. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163–1167
  50. Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow up of renal cell carcinoma based on pathological stage. J Urol. 1995;154:28–31
  51. Rosen PR, Murphy KG. Bone scintigraphy in the initial staging of patients with renal-cell carcinoma: Concise communication. J Nucl Med. 1984;25:289–291
  52. Staudenherz A, Steiner B, Puig S, et al. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma?. Cancer. 1999;85:153–155
  53. Wu HC, Yen RF, Shen YY, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas—A preliminary report. J Cancer Res Clin Oncol. 2002;128:503–506
  54. Kang DE, White RL, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–1809
  55. Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma. Clin Nucl Med. 2008;33:894–895
  56. Fonti R, Salvatore B, Quarantelli M, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195–200
  57. Bataille R, Chevalier J, Rossi M, et al. Bone scintigraphy in plasma-cell myeloma (A prospective study of 70 patients). Radiology. 1982;145:801–804
  58. D'Sa S, Abildgaard N, Tighe J, et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol. 2007;137:49–63
  59. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646–1653
  60. Alexandrakis MG, Kyriakou DS, Passam FH, et al. Correlation between the uptake of Tc99m-sestamibi and prognostic factors in patients with multiple myeloma. Clin Lab Hematol. 2002;24:155–159
  61. Hung G-U, Tsai C-C, Tsai S-C, et al. Comparison of Tc99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Res. 2005;25:4737–4741
  62. Durie BGM. The role of anatomic and functional staging in myeloma: Description of Durie/salmon plus staging system. Eur J Cancer. 2006;42:1539–1543
  63. Kato T, Tsukamoto E, Nishioka T, et al. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med. 2000;25:870–873
  64. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:361–366
  65. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184:1199–1204
  66. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507
  67. Durie BGM, Kyle RA, Belch A, et al. Myeloma management guidelines: A consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J. 2003;4:379–398
  68. Dankerl A, Liebisch P, Glatting G, et al. Multiple myeloma: Molecular imaging with 11C-methionine PET/CT—Initial experience. Radiology. 2007;242:498–508
  69. Falini B, Canino S, Sacchi S, et al. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. Br J Haematol. 1988;69:311–320
  70. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340:858–868
  71. Oberg K. Neuroendocrine gastrointestinal tumors—A condensed overview of diagnosis and treatment. Ann Oncol. 1999;10:3–8
  72. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999;229:815–821
  73. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  74. Wallace S, Ajani JA, Charnsangavej C, et al. Carcinoid tumors: Imaging procedures and interventional radiology. World J Surg. 1996;20:147–156
  75. Meijer WG, van der Veer E, Jager PL, et al. Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003;44:184–191
  76. Zuetenhorst JM, Hoefnageli CA, Boot H, et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun. 2002;23:735–741
  77. Ross EM, Roberts WC. The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. 1985;79:339–354
  78. Scarsbrook AF, Ganeshan A, Statham J, et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics. 2007;27:455–477
  79. Leboulleux S, Dromain C, Vataire AL, et al. Prediction and diagnosis of bone metastases in well-differentiated gastroenteropancreatic endocrine cancer: A prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 2008;93:3021–3028
  80. Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med. 2001;42:998–1004
  81. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumors. Clin Endocrinol (Oxf). 2003;59:565–573
  82. Pfannenberg AC, Eschmann SM, Horger M, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835–843
  83. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med. 1998;25:79–83
  84. Eriksson B, Orlefors H, Oberg K, et al. Developments in PET for the detection of endocrine tumors. Best Pract Res Clin Endocrinol Metab. 2005;19:311–324
  85. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26:1489–1495
  86. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-dota-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518
  87. Baum RP, Niesen A, Leonhardi J, et al. Receptor PET/CT imaging of neuroendocrine tumors using theGa-68 labelled, high affinity somatostatin analogue DOTA-1-Nal3-octreotide (DOTA-NOC): clinical results in 327 patients. Eur J Nucl Med Mol Imaging. 2005;32:s54
  88. Lynn MD, Braunstein EM, Shapiro B. Pheochromocytoma presenting as musculoskeletal pain from bone metastases. Skeletal Radiol. 1987;16:552–555
  89. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res. 2005;37:717–721
  90. Krausz Y, Israel O. Single-photon emission computed tomography/computed tomography in endocrinology. Semin Nucl Med. 2006;36:267–274
  91. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabelled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1–6
  92. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902
  93. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083–4087
  94. Shulkin BL, Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125–1131
  95. Shulkin BL, Ilias I, Sisson JC, et al. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci. 2006;1073:374–382
  96. Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology. 1999;212:35–41
  97. Mamede M, Carrasquillo JA, Chen CC, et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-d-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun. 2006;27:31–36
  98. Bouvier JF, Philip T, Chauvot P, et al. Pitfalls and solutions in neuroblastoma diagnosis using radioiodine MIBG: Our experience about 50 cases. Prog Clin Biol Res. 1988;271:707–720
  99. Sofka CM, Semelka RC, Kelekis NL, et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging. 1999;17:193–198
  100. Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood (Their value in the diagnosis, staging and assessment of response to therapy). Q J Nucl Med. 2003;47:31–40
  101. Taggart D, Dubois S, Matthay KK. Radiolabelled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403–418
  102. Barai S, Bandopadhayaya GP, Malhotra A, et al. Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma?. J Postgrad Med. 2004;50:257–260
  103. Cheung N-KV, Kushner BH. Should we replace bone scintigraphy plus CT with MR imaging for staging of neuroblastoma?. Radiology. 2003;226:286–287
  104. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679–688
  105. Dowell HM, Losty P, Barnes N, et al. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;52:552
  106. Shulkin BL, Wieland DM, Baro ME, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21
  107. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma (Groupe d'etudes des tumeurs a calcitonin (GETC)). J Clin Endocrinol Metab. 2000;85:919–922
  108. Perault C, Schvartz C, Wampach H, et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas (The group of thyroid tumoral pathology of Champagne-Ardenne). J Nucl Med. 1997;38:1234–1242
  109. de Groot JW, Links TP, Jager PL, et al. Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11:786–794
  110. Diehl M, Risse JH, Brandt-Mainz K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicenter study. Eur J Nucl Med. 2001;28:1671–1676
  111. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–4190
  112. Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221–226
  113. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: What is the impact of each modality?. Eur J Nucl Med Mol Imaging. 2007;34:487–495
  114. Zuijdwijk MD, Vogel WV, Corstens FHM, et al. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2008;29:636–641
  115. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32:690–695
  116. Brandt-Mainz K, Muller SP, Gorges R, et al. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27:490–496

PII: S0001-2998(09)00047-6

doi: 10.1053/j.semnuclmed.2009.07.002

Seminars in Nuclear Medicine
Volume 39, Issue 6 , Pages 416-430 , November 2009

Article Tools

* Image Usage & Resolution